About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, February 29th, 2016

The QualityStocks
Daily Stock List


Rock Creek Pharmaceuticals, Inc. (RCPI)

Stock News Now reported this month on Rock Creek Pharmaceuticals, Inc. (RCPI), StreetInsider and Jason Bond did earlier, and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Rock Creek Pharmaceuticals, Inc. is a clinical stage drug development company. It focuses on the application of its lead compound undergoing development to treat chronic inflammatory conditions. Essentially, Rock Creek is an emerging drug development company concentrating on the discovery, development and commercialization of new drugs, formulations and compounds that provide therapies for chronic and acute inflammatory diseases. The Company is headquartered in Sarasota, Florida.

Rock Creek Pharmaceuticals’ lead compound, Anatabine Citrate, is a small molecule, cholinergic agonist. It exhibits anti-inflammatory pharmacological characteristics, different from other anti-inflammatory drugs available, including biologics, steroids and non-steroidal anti-inflammatories.

The Company has sponsored extensive pre-clinical (in vitro and in vivo) studies resulting in peer reviewed and published scientific journal articles, covering models of Multiple Sclerosis, Alzheimer's Disease, and Auto-Immune Thyroiditis. Rock Creek’s compounds are cholinergic receptor ligands. They imitate the activity of the endogenous neurotransmitter acetylcholine.

Rock Creek Pharmaceuticals earlier announced the successful completion of its three-part Phase I clinical trial that took place in the United Kingdom (UK).  The overall aim of the Phase I trial was to evaluate safety, tolerability and pharmacokinetic (PK) profiles of different formulations of its lead compound, Anatabine Citrate, in healthy volunteers.

With the completion of this Phase I oral dosing trial, Rock Creek is now prepared to conduct a proof-of-concept clinical trial. This is to investigate the safety and efficacy of topical formulations of its lead compound in patients suffering from mild-to-moderate psoriasis.

In early February, Rock Creek Pharmaceuticals announced that it received an interim report of the pharmacodynamic (PD) results of its Phase I clinical trial of its lead compound, anatabine citrate. The Phase I trial, approved by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), demonstrated that the drug was safe, well tolerated and had a consistent pharmacokinetic (PK) profile. The PD report underlined that anatabine citrate produced considerable reductions in a key marker of inflammation, STAT 3 (Signal Transducer and Activator of Transcription 3), in human volunteers.

Rock Creek Pharmaceuticals, Inc. (RCPI), closed Monday's trading session at $0.4801, down 3.98%, on 30,012 volume with 19 trades. The average volume for the last 60 days is 50,198 and the stock's 52-week low/high is $0.49/$4.29.

ProtoKinetix, Inc. (PKTX)

SmallCapVoice and TopPennyStockMovers reported on ProtoKinetix, Inc. (PKTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

ProtoKinetix, Inc. is a molecular biotechnology company based in St. Mary’s, West Virginia. It has developed and patented a family of hyper stable, potent glycopeptides (Anti-Aging GlycoPeptide - AAGP™) that enhance the therapeutic results and decrease the cost of stem cell medicine. Because of the anti-inflammatory effect of AAGP™ molecules, ProtoKinetix is now targeting the direct treatment of diseases, which have a major inflammatory component. The Company’s molecule, AAGP™, is an antifreeze glycopeptide. It imitates a naturally occurring glycoprotein found in Arctic fish.

ProtoKinetix has wide-ranging patent protection for its portfolio of anti-aging glycopeptides. The Company’s anti-aging glycopeptide, trademarked AAGP™, is a small (580.96 Daltons), stable, synthetic replicas of the larger (>2,600 Daltons), less stable AFGP that has been found to have protective properties in nature. The small size of AAGP™ enables it to penetrate cells and permits it to pass through cell and capillary junctions in vivo.

In addition, its bioactivity at a range of pHs (5.3-10.3) and temperatures (-196°C to 22°C) and efficiency at concentrations (1mg/ml) is well below its toxic dose (50mg/ml). This makes it a candidate to enter into the next stages of translational research. AAGPs™ were invented by Dr. Geraldine-Castelot-Deliencourt and developed and protected by patents in partnership with the Institute for Scientific Application (INSA) of France.

ProtoKinetix has also developed a large body of trade secrets and knowledge vis-à-vis the development, use, and manufacture of AAGP™. This includes, but is not limited to, the optimization of materials for efforts, and how to maximize sensitivity, speed-to-result, specificity, stability, purity, and reproducibility. The Company is building value via the independent research of laboratories into applications for its AAGP™ molecule.

Due to the results realized over the last three years of testing, ProtoKinetix is presently preparing a submission to enter into Phase one and two human clinical trials. More studies will be expanded to include whole organ transplantation. The Company’s AAGP™ molecule is helping to greatly improve the efficacy of Cell Transplant Treatments for diabetes. This is a procedure that transplants insulin producing islet to make them insulin independent for periods of time.

In 2015, AAGP™ was presented at the Congress of the International Pancreas and Islet Transplant Association in Melbourne, Australia in November. Additionally, the Company completed an intense, 3-year islet transplantation study with the University of Alberta. At present, ProtoKinetix has completed a peer review and has been published in the respected, American Diabetes Association’s Journal: Diabetes. The Company is continuing to study the effects of AAGP™ on Non-Obese Diabetic mice at the Dr. James Shapiro Lab in Edmonton at the University of Alberta.

ProtoKinetix, Inc. (PKTX), closed Monday's trading session at $0.055, up 12.61%, on 3,000 volume with 3 trades. The average volume for the last 60 days is 61,553 and the stock's 52-week low/high is $0.0351/$0.15.

Oncolytics Biotech, Inc. (ONCYF)

Today we are highlighting Oncolytics Biotech, Inc. (ONCYF), here at the QualityStocks Daily Newsletter.

Oncolytics Biotech, Inc. is biotechnology company concentrating on the development of oncolytic viruses as potential cancer therapeutics. The Company’s clinical program includes an array of later-stage, randomized human trials in various indications using REOLYSIN®. This is Oncolytics’ proprietary formulation of the human reovirus. Oncolytics Biotech has its corporate headquarters in Calgary, Alberta. The Company’s shares trade on the OTC Markets Group’s OTCQB.

REOLYSIN® is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus. REOLYSIN® is presently entering into late stage (Phase III) clinical testing. REOLYSIN® has been used in more than 30 clinical trials including translational, Phase I, Phase II (single arm and randomized), and Phase III studies in a wide spectrum of cancer indications.

In clinical trials, REOLYSIN® has been shown to be well-tolerated, with patients showing only mild, flu-like symptoms. REOLYSIN® has been used alone and in combination with biologics, chemotherapy, as well as radiotherapy for different cancers.

In December 2015, Oncolytics Biotech announced that Dr. D.W. Sborov and colleagues made a poster presentation at the 57th American Society of Hematology (ASH) Annual Meeting. The poster presentation, titled "REOLYSIN® Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients," reveals updated findings from a pilot study (NCI-9603) in patients with relapsed or refractory multiple myeloma treated using the combination of carfilzomib and REOLYSIN®.

Highlights of the data presented include all seven patients treated at the full clinical dose had a clinical response. Patients treated at the full clinical dose (dose level 1) had a deeper and lengthier response than those treated at dose level minus 1. The combination of carfilzomib and REOLYSIN® produced a significant (p=0.005) increase in caspase-3, a marker associated with apoptotic (programmed) cell death, but to a higher degree in those patients treated at dose level 1.

The treatment combination was associated with an increased infiltration of CD8+ T-cells and the significant (p=0.005) upregulation of PD-L1. This suggests that the addition of a PD-1 or PD-L1 inhibitor may further optimize the treatment regimen.

Last week, Oncolytics Biotech announced that it entered into an "at-the-market" (ATM) equity distribution agreement dated February 25, 2016 with Canaccord Genuity Corp. acting as sole and exclusive agent. With this Agreement, Oncolytics Biotech may, from time to time and until March 16, 2018, sell common shares having a collective offering value of up to $4.6 million, solely at Oncolytics’ discretion.

Oncolytics Biotech, Inc. (ONCYF), closed Monday's trading session at $0.2748, down 5.34%, on 99,695 volume with 22 trades. The average volume for the last 60 days is 93,973 and the stock's 52-week low/high is $0.24/$1.40.

Peregrine Pharmaceuticals, Inc. (PPHM)

Pennybuster, StreetInsider, Stock Shock and Awe, Zacks, BUYINS.NET, and PennyStocks24 reported on Peregrine Pharmaceuticals, Inc. (PPHM), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

Peregrine Pharmaceuticals, Inc. is a bio-pharmaceutical company that holds various antibodies for the treatment of cancer in clinical trials. The Company is a clinical-stage enterprise developing first-in-class monoclonal antibodies centered on the treatment and diagnosis of cancer. Peregrine Pharmaceuticals lists on the Nasdaq Capital Market. The Company is headquartered in Tustin, California.

Peregrine Pharmaceuticals also has in-house cGMP manufacturing capabilities by way of its wholly-owned subsidiary Avid Bioservices, Inc. Avid provides development and biomanufacturing services for Peregrine and outside customers. Peregrine’s contract manufacturing business conducted through Avid Bioservices has shown consistent revenue growth.

Peregrine Pharmaceuticals is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. The Company is advancing the development of its later-stage product candidates in numerous continuing clinical programs. It is also seeking strategic alliances to widen the geographic reach of its development programs or to advance its earlier-stage technologies and product candidates.

The lead candidate from Peregrine Pharmaceuticals’ Tumor Necrosis Therapy (TNT) platform is the aforementioned Cotara®. This is a novel therapy positioned for Phase III clinical development for the treatment of glioblastoma multiforme (GBM).

Last week, Peregrine Pharmaceuticals announced after Thursday's market close that it would stop the ongoing Phase III SUNRISE trial of bavituximab in patients with previously treated cell lung cancer. Peregrine noted that its decision to discontinue the trial was based on the recommendation of the study's Independent Data Monitoring Committee (IDMC) following an interim analysis. It demonstrated the therapy did not show a sufficient improvement in patients’ overall survival.

Mr. Steven W. King, Peregrine Pharmaceuticals’ President and Chief Executive Officer, said, "While this is an unexpected and disappointing setback for the bavituximab chemotherapy combination clinical program, we have not seen anything in this trial result that diminishes our enthusiasm for advancing our immuno-oncology (I-O) combination trials. The I-O combination studies are based on different mechanistic synergies that are clearly separate from the chemotherapy combination being evaluated in the SUNRISE study.”

Peregrine Pharmaceuticals, Inc. (PPHM), closed Monday's trading session at $0.4001, down 1.96%, on 6,570,367 volume with 5,786 trades. The average volume for the last 60 days is 1,253,842 and the stock's 52-week low/high is $0.37/$1.66.

ICTV Brands, Inc. (ICTV)

Today we are reporting on ICTV Brands, Inc. (ICTV), here at the QualityStocks Daily Newsletter.

ICTV Brands, Inc. is a digitally focused direct response marketing and global branding enterprise. The Company sells various health, wellness and beauty products by way of a multi-channel distribution strategy. ICTV Brands’ products are mainly sold in the United States. Moreover, they are available in more than 60 countries. ICTV Brands has its corporate headquarters in Wayne, Pennsylvania.

The Company employs a unique marketing strategy and multi-channel distribution model to develop, market and sell products via direct response television (DRTV), Internet/digital, e-commerce, live television shopping, as well as retail. ICTV’s products include DermaWand. This is a skin care device that decreases the appearance of fine lines and wrinkles, and helps improve skin tone and texture.

The Company’s products also include DermaVital. This is a professional quality skin care line, which effects premier hydration. ICTV also has its CoralActives brand of acne treatment and skin cleansing products. Furthermore, ICTV products include Derma Brilliance, a sonic exfoliation skin care system that helps reduce visible signs of aging; Jidue, a facial massager device that helps alleviate stress; and Good Planet Super Solution, a multi-use cleaning agent.

This past January, ICTV Brands announced it acquired the global ownership of the DermaWand patent and all related trademarks. Under the Purchase Agreement entered into on January 22, 2016 with Omega 5 Technologies, Inc., ICTV Brands acquired the DermaWand patent and all related trademarks for the sum of $1,200,000.

Mr. Kelvin Claney, Chief Executive Officer and Chairman of ICTV Brands, stated "After over fifteen years of working with Omega, we are delighted to have reached this agreement whereby ICTV now officially owns the DermaWand brand outright. We are confident that the buyout will bring us considerable financial flexibility as we continue to grow DermaWand both domestically and internationally into various sales channels. Owning both the patent and trademarks is a significant asset for our Company, and we're excited for DermaWand and ICTV's continued growth."

ICTV Brands, Inc. (ICTV), closed Monday's trading session at $0.2168, up 7.06%, on 29,100 volume with 12 trades. The average volume for the last 60 days is 18,222 and the stock's 52-week low/high is $0.155/$0.69.


The QualityStocks
Company Corner


OurPet's Company (OPCO)

The QualityStocks Daily Newsletter would like to spotlight OurPet's Company (OPCO). Today, OurPet's Company closed trading at $0.90, even for the day, on 1,000 volume with 1 trade. The stock’s average daily volume over the past 60 days is 3,957, and its 52-week low/high is $0.45/$1.00.

OurPet's Company today reported record net revenue and record net income for the three months and twelve months ended December 31, 2015. Net income increased 10% to a record $450,592 for the 2015 fourth quarter from $409,341 for the same period in 2014. For the 2015 full-year, net income increased approximately 74% to a record $1,336,912 from $769,275 the prior year. Net income was $0.02 for both fourth quarter periods and increased to a full-year record $0.07 in 2015 from $0.04 in 2014. The 2015 fourth quarter and full-year results benefited from specific management initiatives that resulted in lower fixed costs, lower product costs and lower selling, general and administrative expenses.

OurPet's Company (OPCO) develops, produces and markets various pet accessory and consumable products designed to awaken pets' natural instincts, be it in feeding, playing or waste management. Sold globally through pet specialty retailers, food, drug and mass chains, e-commerce and international channels, the company's products are marketed under a the OurPets®, Pet Zone® and PetTastic® brands with well-known sub-brands such as Play-N-Squeak™, Cosmic Catnip™, Durapet, SmartScoop and Flappy. In total, OurPet's has an intellectual property portfolio featuring more than 160 individual patents, giving the company sustainable access to the pet products industry for the foreseeable future.

In recent years, the U.S. pet products and services market has experienced strong growth, with total sales accounting for approximately $73 billion in 2014, according to a report by Packaged Facts. In 2015, this strong performance is expected to continue, building on the recent rise in related ecommerce purchases, as well as an uptick in dog and cat ownership throughout the country. In order to capitalize on this market performance, OurPet's maintains an ongoing new product development program to continually keep an evolutionary and revolutionary new product pipeline feeding its offerings. In July 2015, OurPet's introduced many new products at the national Super Zoo trade show in Las Vegas such as the Catty Whack®, Designer Diner™/Barking Bistro™ and the Zoom Plume™.

The company's capitalization strategy is guided by a management team of experienced industry professionals dedicated to further strengthening its product portfolio through aggressive development of innovative products. Management has a proven track-record of leveraging deep knowledge in the innovation, technology, distribution and pet markets to successfully push through adverse market conditions to achieve increases in revenue, margins and net income.

OurPet's, through its innovative and extensive line of popular pet products, is in a favorable strategic position to continue building upon its recent market growth. For prospective shareholders, this positioning makes the company an intriguing investment opportunity in the months to come. Look for OurPet's to capitalize on steady market performance moving forward, providing an opportunity for the company to realize strong investor returns in the future. Disclaimer

OurPet's Company Company Blog

OurPet's Company News:

OurPet's Company Reports Record 2015 Fourth Quarter and Full-Year Results

OurPet's (OPCO) Expects New Product Line to Make Big Splash at Global Pet Expo

OurPet's Commits to Further Innovation in Pet Products That Enhance Pet/Owner Relationship

Agora Holdings, Inc. (AGHI)

The QualityStocks Daily Newsletter would like to spotlight Agora Holdings, Inc. (AGHI). Today, Agora Holdings, Inc. closed trading at $0.388, off by 3.00%, on 146,357 volume with 71 trades. The stock’s average daily volume over the past 60 days is 184,868, and its 52-week low/high is $0.03/$2.50.

Agora Holdings, Inc. has enhanced its FRAME social media management software for optimal use by businesses, public relations (PR) and investor relations (IR) agencies. FRAME's unique technology allows companies to use a single dashboard to publish brand-relevant messages to all of an organization's corporate social media accounts. This enables the company to build campaigns in a faster, more efficient, and easier way.

Agora Holdings, Inc. (AGHI), together with its wholly-owned subsidiary, Geegle Media, is leading a diversified family entertainment and media enterprise through business segments which include: TV on Demand, interactive media, business products and consumer platforms. With its multi-dimensional approach, Geegle Media supports Agora Holdings' mission to deliver innovate and high-quality business solution products and to deliver video content from around the world.

Geegle Media web platforms include; GeegleTV, Frame, 1000Salads, RealtyTV and LobbyTV. Geegle TV is a multi-platform video entertainment website that curates high-quality video content from around the world. In 2016, GeegleTV will serve as co-producer by airing original content. By exposing undiscovered content to millions of users and rendering it shareable to social media, Geegle TV will serve as a marketing partner to local and internationally based TV shows not yet on the open market.

For commercial use, Geegle Media provides a variety of solutions that include web development and billing software for VoIP applications. RealtyTV is its state-of-the-art platform for real estate brokerages. LobbyTV is another of its widely used products by business offices. For individuals, Geegle TV combines radio, On Demand movies, news, sports and children's content.

Geegle Media is also developing 1000salads, an online hub that encourages healthy lifestyles. The portal will feature recipes and products, health-oriented articles and a curated selection of local restaurants and grocers that deliver to the health-conscious user. Currently in its alpha stage of development, 1000salads is gearing up its sales and marketing in preparation for its launch in 2016.

Geegle Media differs from other On Demand providers, such as Netflix and HBO, in that its service is free of constraints such as subscription, fees and penalties. As consumers increasingly opt for personalized sources of entertainment, Agora recognizes the vast opportunities and growth potential provided by the rising popularity of TV On Demand. The company also benefits from strong and visionary management with a track record of bringing innovative ideas to fruition. Disclaimer

Agora Holdings, Inc. Company Blog

Agora Holdings, Inc. News:

Agora Holdings Inc.'s Geegle Media Unveils Optimized FRAME for Business Use

Agora Holdings, Inc., (OTCMKTS: AGHI) Analyst Coverage; Preparation for the Launch of FRAME

Agora Holdings Inc.'s Geegle Media Set to Release FRAME This Month

Immune Therapeutics, Inc. (IMUN)

The QualityStocks Daily Newsletter would like to spotlight Immune Therapeutics, Inc. (IMUN). Today, Immune Therapeutics, Inc. closed trading at $0.1709, up 0.53%, on 586,443 volume with 103 trades. The stock’s average daily volume over the past 60 days is 127,280, and its 52-week low/high is $0.045/$0.36.

Immune Therapeutics, Inc. (IMUN) is a biotechnology company applying its patented immunotherapy to combat chronic, life-threatening diseases that affect persons around the world. Building on the power of the body's natural immune system, the company's pipeline of products and immunotherapy technologies are designed to enhance treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and a variety of autoimmune diseases.

Immune Therapeutics' most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its low dose naltrexone product (LDN), internationally known as Lodonal™, both of which have been shown to stimulate immune systems even in patients with advanced cancer.

Additionally, Immune Therapeutics is pursuing additional investigations for MENK and LDN as viable treatments for autoimmune conditions such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.

Immune Therapeutics and partners AHAR Pharma and GB Pharma Holdings recently completed a bridging trial to determine the safety and efficacy of LDN in patients with HIV, and have submitted data in connection with the filing of its New Drug Application for LDN with The National Agency for Food and Drug Administration and Control, (NAFDAC) of Nigeria. Disclaimer

Immune Therapeutics, Inc. Company Blog

Immune Therapeutics, Inc. News:

Immune Therapeutics, Inc to Present at the SeeThruEquity & The Brewer Group 2nd Annual Innovations Investor Conference at the Ritz in South Beach on Feb. 22, 2016

SeeThruEquity Initiates Coverage on Immune Therapeutics, Inc. with a Price Target of $0.61

Immune Therapeutics, Inc. Announced the Completion of the Bridging Trial

Cherubim Interests, Inc. (CHIT)

The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0001, even for the day. The stock’s average daily volume over the past 60 days is 64,064,925, and its 52-week low/high is $0.00001/$0.33.

Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.

The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer

Cherubim Interests, Inc. Company Blog

Cherubim Interests, Inc. News:

Moving Ahead of Averages, Technical Review -- Research on Saleen Automotive, Cherubim Interests, Fission Uranium, and Pure Biosciences

Cherubim Interests, Inc. Signs MOU to Acquire Revenue-Producing Company

Cherubim Interests Inc. Announces FINRA Approval of Convertible Preferred Stock Dividend

View Systems, Inc. (VSYM)

The QualityStocks Daily Newsletter would like to spotlight View Systems, Inc. (VSYM). Today, View Systems, Inc. closed trading at $0.0014, off by 22.22%, on 571,700 volume with 15 trades. The stock’s average daily volume over the past 60 days is 578,416, and its 52-week low/high is $0.0011/$0.015.

View Systems, Inc. (VSYM) is a leading security technology products company with “state-of-the-art” technological solutions for modern security problems. Targeting the challenging business opportunities in the opening decades of the 21st century and beyond, View Systems has solutions for law enforcement facilities such as correctional institutions as well as other government agencies, schools, courthouses, event and sports venues, the military and commercial businesses.

The senior management team is comprised of successful businessmen with decades of business and professional experience in the security industry. The approach used by View Systems utilizes the expertise of this team to provide innovative solutions to security problems with reliable “cutting edge” products in conjunction with client-oriented security consulting services.

The company’s flagship product, ViewScan, is an advanced walk-through Concealed Weapons Detection System (CWD) that greatly simplifies the process of discriminating suspicious items from harmless ones. The highly sensitive, completely passive sensor technology powering the system accurately detects the location and number of threat objects such as knives, guns and razor blades while ignoring personal artifacts like coins, keys and belt buckles. A portable version of this system has only a fifteen minute setup time using only a screwdriver and it easily fits inside a golf size case.

Experts say the security industry has been the fastest-growing sector of the global economy during the past decade. Today, it is conservatively estimated to be a $100 billion-a-year industry and growing. As the business environment continues to get more complex, especially in foreign markets, View Systems is strategically positioned to capitalize on unsurpassed opportunity. Disclaimer

View Systems, Inc. Company Blog

View Systems, Inc. News:

View Systems, Inc. (VSYM) to Acquire Y.M. Advantage, Inc.

View Systems in Discussions With Three M&A Candidates and Reviewing Letter of Intent

View Systems, Inc. Files for Patent, Begins Manufacturing of Enhanced ViewScan Product


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters





BioSolar Newsletter



By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251